Article

Anti psychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia - A systematic review

Department of Psychiatry, Bipolar Disorder Research Center at the Mood Disorders Program, University Hospitals Case Medical Center/Case Western Reserve University, School of Medicine, Cleveland, OH, USA.
Journal of Clinical Psychopharmacology (Impact Factor: 3.76). 05/2008; 28(2):203-9. DOI: 10.1097/JCP.0b013e318166c4d5
Source: PubMed

ABSTRACT Newer atypical antipsychotics have been reported to cause a lower incidence of extrapyramidal side effects (EPS) than conventional agents. This review is to compare antipsychotic-induced EPS relative to placebo in bipolar disorder (BPD) and schizophrenia.
English-language literature cited in Medline was searched with terms antipsychotics, placebo-controlled trial, and bipolar disorder or schizophrenia and then with antipsychotic (generic/brand name), safety, akathisia, EPS, or anticholinergic use, bipolar mania/depression, BPD, or schizophrenia, and randomized clinical trial. Randomized, double-blind, placebo-controlled, monotherapy studies with comparable doses in both BPD and schizophrenia were included. Absolute risk increase and number needed to treat to harm (NNTH) for akathisia, overall EPS, and anticholinergic use relative to placebo were estimated.
Eleven trials in mania, 4 in bipolar depression, and 8 in schizophrenia were included. Haloperidol significantly increased the risk for akathisia, overall EPS, and anticholinergic use in both mania and schizophrenia, with a larger magnitude in mania, an NNTH for akathisia of 4 versus 7, EPS of 3 versus 5, and anticholinergic use of 2 versus 4, respectively Among atypical antipsychotics, only ziprasidone significantly increased the risk for overall EPS and anticholinergic use in both mania and schizophrenia, again with larger differences in mania, an NNTH for overall EPS of 11 versus 19, and anticholinergic use of 5 versus 9. In addition, risks were significantly increased for overall EPS (NNTH = 5) and anticholinergic use (NNTH = 5) in risperidone-treated mania, akathisia in aripiprazole-treated mania (NNTH = 9) and bipolar depression (NNTH = 5), and overall EPS (NNTH = 19) in quetiapine-treated bipolar depression.
Bipolar patients, especially in depression, were more vulnerable to having acute antipsychotic-induced movement disorders than those with schizophrenia.

Download full-text

Full-text

Available from: Keming Gao, Aug 27, 2015
0 Followers
 · 
115 Views
  • Source
    • "Mood stabilizers may be protective for brain structure and function (Emsell and McDonald, 2009; Benedetti et al., 2011), but whether saccade accuracy is restored with mood stabilizer treatment requires further investigation. Higher rates of extrapyramidal effects of antipsychotic medication have been noted in bipolar disorder compared with schizophrenia (Gao et al., 2008). Our data may be consistent with this in that prior to treatment, BDP patients showed a motor system disturbance that schizophrenia patients did not. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurocognitive deficits are associated with most psychotic disorders, but may differ across diagnosis and by treatment status. This ambiguity is partly addressed in longitudinal pre/post treatment studies with first episode patients. Antipsychotic-naïve first-episode schizophrenia patients have shown intact performance on a predictive saccade task that assesses simple motor learning, spatial abilities, and response planning. After antipsychotic treatment, however, schizophrenia patients performing this task show a selective impairment in the accuracy of anticipatory responses, generated from learned internal representations of the task stimulus. This finding is in line with other observations of antipsychotic medication effects on frontostriatal systems, particularly dorsolateral prefrontal cortex. We sought to replicate this provocative finding with an independent sample of antipsychotic-naïve first-episode schizophrenia patients and extend it by including a group of patients with first episode bipolar disorder with psychosis (BDP). Matched healthy controls were also studied in parallel. Schizophrenia patients demonstrated intact performance pretreatment followed by impairment post-treatment for accuracy of anticipatory responses, and worse accuracy was associated with higher antipsychotic dose. BDP patients displayed saccade accuracy deficits before and after treatment and had no correlation of performance and antipsychotic dose. The findings suggest different neural alterations early in the course of each psychotic disorder, and different vulnerabilities to antipsychotic treatment effects between schizophrenia and BDP.
    Schizophrenia Research 08/2014; 159(1). DOI:10.1016/j.schres.2014.07.028 · 4.43 Impact Factor
  • Source
    • "This may be due to the very attenuated cataleptic response observed in muscarinic M 4 −/− mice at lower doses of haloperidol and risperidone, making it more difficult to establish a further significant reduction. Risperidone is a second generation antipsychotic which at lower doses only causes few motor adverse events in patients but at higher doses converges to the side effect profile of haloperidol (Gao et al., 2008). A similar profile is observed in rodents, where risperidone at high doses causes Fosinduction in the motor-related dorsolateral striatum in a manner similar to the effect of haloperidol (Fink-Jensen and Kristensen, 1994). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A delicate balance exists between the central dopaminergic and cholinergic neurotransmitter systems with respect to motor function. An imbalance can result in motor dysfunction as observed in Parkinson's disease patients and in patients treated with antipsychotic compounds. Cholinergic receptor antagonists can alleviate extrapyramidal symptoms in Parkinson's disease and motor side effects induced by antipsychotics. The effects of anticholinergics are mediated by muscarinic receptors of which five subtypes (M(1)-M(5)) exist. Muscarinic M(4) receptors are found at high concentrations in motor parts of the striatum, suggesting a role for muscarinic M(4) receptors in the motor side effects of antipsychotics, and in the alleviation of these side effects by anticholinergics. Here we investigated the potential role of the muscarinic M(4) receptor in catalepsy induced by antipsychotics (haloperidol and risperidone) as well as the anti-cataleptic effects of the non-selective anticholinergic drug scopolamine in fully backcrossed muscarinic M(4) receptor knockout mice. The drug-induced catalepsy was strongly attenuated, but not abolished, in M(4) knockout mice as compared to wild-type controls. Scopolamine further attenuated the cataleptic response in M(4) knockout mice, suggesting that non-M(4) muscarinic receptors also participate in the anti-cataleptic effects. In conclusion, these data indicate an important role for M(4) receptors in antipsychotic-induced motor side effects and suggest that M(4) receptors could be a target for future pharmacological treatment of antipsychotic-induced as well as idiopathic parkinsonism.
    European journal of pharmacology 04/2011; 656(1-3):39-44. DOI:10.1016/j.ejphar.2011.01.018 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive impairments of attention, memory and executive functions are a fundamental feature of the pathophysiology of schizophrenia. The neurophysiological and neurochemical changes in the auditory cortex are shown to underlie cognitive impairmentsin schizophrenia patients. Functional state of the neural substrate of auditory information processing could be objectively and non-invasively probed with auditory event-related potentials (ERPs) and event- related fields (ERFs). In the current work, we explored the neurochemical effect on the neural origins of auditory information processing in relation to schizophrenia. By means of ERPs/ERFs we aimed to determine how neural substrates of auditory information processing are modulated by antipsychotic medication in schizophrenia spectrum patients (Studies I, II) and by neuropharmacological challenges in healthy human subjects (Studies III, IV). First, with auditory ERPs we investigated the effects of olanzapine (Study I) and risperidone (Study II) in a group of patients with schizophrenia spectrum disorders. After 2 and 4 weeks of treatment, olanzapine has no significant effects on mismatch negativity(MMN) and P300, which, as it has been suggested, respectively reflect preattentive and attention-dependent information processing. After 2 weeks of treatment, risperidone has no significant effect on P300, however risperidone reduces P200 amplitude. This latter effect of risperidone on neural resources responsible for P200 generation could be partly explained through the action of dopamine. Subsequently, we used simultaneous EEG/MEG to investigate the effects of memantine (Study III) and methylphenidate (Study IV) in healthy subjects. We found that memantine modulates MMN response without changing other ERP components. This could be interpreted as being due to the possible influence of memantine through the NMDA receptors on auditory change- detection mechanism, with processing of auditory stimuli remaining otherwise unchanged. Further, we found that methylphenidate does not modulate the MMN response. This finding could indicate no association between catecholaminergic activities and electrophysiological measures of preattentive auditory discrimination processes reflected in the MMN. However, methylphenidate decreases the P200 amplitudes. This could be interpreted as a modulation of auditory information processing reflected in P200 by dopaminergic and noradrenergic systems. Taken together, our set of studies indicates a complex pattern of neurochemical influences produced by the antipsychotic drugs in the neural substrate of auditory information processing in patients with schizophrenia spectrum disorders and by the pharmacological challenges in healthy subjects studied with ERPs and ERFs. Skitsofreniapotilailla on usein psykoottisten oireiden ohella kognitiivisia ongelmia esimerkiksi muistissa ja tarkkavaisuudessa, joihin vanhemmilla psykoosilääkkeillä ei ole vaikutusta. Viime vuosina on kehitetty uusia psykoosilääkkeitä, joiden on arveltu parantavan kognitiivisia oireita. Tässä työssä haluttiin selvittää uusien psykoosilääkkeiden vaikutuksia aivosähköisiin kognitiivisiin mittareihin elektroenkefalografia (EEG)-menetelmällä skitsofreniaspektrin potilailla. 4-viikon mittaisilla risperidoni- ja olantsapiinihoidoilla ei ollut vaikutusta mismatch negatiivisuus - eli MMN - ja P3-vasteisiin, jotka heijastavat tarkkaavaisuusprosessien eri vaiheita. Kuitenkin risperidoni pienensi P2-vastetta, mikä voi heijastaa muutosta potilaiden kognitiivisissa toiminnoissa. Yhdistetyllä MEG/EEG-menetelmällä tutkittiin terveillä koehenkilöillä metyylifenidaatin ja memantiinin vaikutuksia MMN-vasteeseen, jotta saataisiin selvyyttä tarkkaavaisuuden neurokemiallisesta säätelystä. Kerta-annos metyylifenitaaattia ei vaikuttanut MMN-vasteeseen, mutta se pienensi P2-vastetta. Kerta-annos memantiinia suurensi MMN-vastetta EEG:ssä, muttei magnetoenkefalografiassa. Kiihdyttävä glutamaattivälittäjäaine saattaa osallistua tarkkaavaisuuden säätelyyn etuaivokuorella. Risperidonilla, muttei olantsapiinillä oli vaikutuksia aivosähköisiin kognitiivisiin mittareihin lyhyen hoidon jälkeen, mikä voi välittyä dopamiinin kautta.
Show more